Gatehouse Bio

Gatehouse Bio is a groundbreaking TechBio company harnessing the power of artificial intelligence to decipher the complex realm of small RNAs (sRNAs) and craft precision oligonucleotides. Founded in 2018 and headquartered in the United States, the company is dedicated to decoding sRNA isoforms for the development of biomarker-guided precision oligonucleotide therapeutics. This is achieved through their innovative AI-powered Code-Breaker™ Platform, which enables the identification and characterization of disease-associated isoforms and the digital design of therapeutics to counteract their effects. The last known investment for Gatehouse Bio was a Convertible Note funding round on 20 September 2023. Notable investors in this round included SOSV and indiebio, signifying the growing interest in the company's innovative approach within the Biotechnology sector. Gatehouse Bio's compelling focus on utilizing AI to unravel the mysteries of sRNAs and design precise therapeutics positions it as a promising player in the biotech landscape, offering potential for significant impact and growth in the future.